ASX RELEASE
29 October 2026

Chairperson's Address to AGM 2026

Nova Eye Medical Limited (ASX: EYE) (**Nova Eye Medical** or the **Company**), is pleased to provide the Chairperson's Address to the Annual General Meeting of Shareholders being held at 10:30am on 29th of October 2026.

Fellow Shareholders,

Over the past 12 months, Nova Eye Medical has continued its trajectory towards growing a globally relevant ophthalmic device company focused on the glaucoma market. The Company delivered strong commercial progress, reporting FY26 sales of US$23.7 million, representing approximately 26% growth on the prior year, while significantly improving profitability and achieving positive EBITDA in the second half of FY26.

Our iTrack™ Advance canaloplasty platform continues to gain traction, particularly in the United States, where our sales growth rate has consistently outpaced that of our industry peers, with considerable runway ahead of us as we grow our market share. Revenue growth has been supported by expanded market penetration, increased sales force productivity, and growing surgeon adoption of our minimally invasive glaucoma technologies.

Importantly, the business has now reached a scale where operating leverage is becoming evident. Gross margins improved, operating losses narrowed substantially, and management expects the Company to achieve positive EBITDA during FY27 while maintaining strong sales growth.

The Board remains focused on disciplined growth, expanding global adoption of iTrack™, increasing shareholder value, and establishing Nova Eye Medical as a leading participant in the large and growing interventional glaucoma market. We have commenced FY27 with confidence, supported by continued sales momentum, improving financial performance, and reaffirmed growth guidance.

On behalf of the Board, I thank our shareholders, employees, surgeons, distributors and patients for their continued support.

Yours sincerely,

Victor Previn

Chairperson

-END-

Authorised for lodgement by the Board of Directors of Nova Eye Medical Limited.

For more information please contact:

Company
Tom Spurling
Managing Director
+61 417 818 658
tspurling@nova-eye.com

Investors
Mark Flynn
Investor Relations
+61 416 068 733
mflynn@nova-eye.com

ABOUT NOVA EYE MEDICAL

Nova Eye Medical Limited is a medical technology company that develops, manufactures and sells a portfolio of proprietary ophthalmic treatment technologies and devices. Used by eye surgeons globally, these technologies include iTrack™ Advance, a minimally invasive consumable glaucoma surgical device that restores the eye's natural outflow pathway to lower pressure inside the eye and to eliminate patient reliance on anti-glaucoma medications for mild-moderate glaucoma. The Molteno3® glaucoma drainage device platform is designed to enhance surgical utility and optimize clinical outcomes for long-term IOP control in cases of severe glaucoma. It also offers the benefit of a simplified and faster surgical procedure. With its sales headquarters based in Fremont, California, Nova Eye Medical is supported by a global network of distribution partners. Manufacturing facilities are located in Fremont, California and Dunedin, New Zealand.

For additional information about Nova Eye Medical and its technologies, please visit: www.nova-eye.com